Mitsubishi UFJ Trust & Banking Corp Sells 41,944 Shares of Medtronic PLC $MDT

Mitsubishi UFJ Trust & Banking Corp decreased its position in Medtronic PLC (NYSE:MDT) by 6.7% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 581,226 shares of the medical technology company’s stock after selling 41,944 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Medtronic were worth $55,833,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Medtronic by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock worth $12,388,027,000 after buying an additional 1,888,381 shares during the last quarter. State Street Corp lifted its position in Medtronic by 1.0% in the 3rd quarter. State Street Corp now owns 60,460,537 shares of the medical technology company’s stock worth $5,800,550,000 after buying an additional 625,992 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Medtronic by 0.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company’s stock worth $2,044,637,000 after buying an additional 192,410 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in Medtronic by 0.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock worth $2,008,278,000 after buying an additional 98,220 shares during the last quarter. Finally, Raymond James Financial Inc. boosted its holdings in Medtronic by 3.0% during the 3rd quarter. Raymond James Financial Inc. now owns 11,203,865 shares of the medical technology company’s stock valued at $1,067,055,000 after acquiring an additional 327,899 shares during the period. Institutional investors own 82.06% of the company’s stock.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.26% of the company’s stock.

Medtronic Trading Down 1.2%

Shares of MDT stock opened at $81.88 on Wednesday. The business has a 50-day moving average of $89.15 and a 200 day moving average of $95.02. The stock has a market capitalization of $105.13 billion, a PE ratio of 22.81, a P/E/G ratio of 2.15 and a beta of 0.75. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. Medtronic PLC has a 1-year low of $79.93 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same quarter last year, the business posted $1.38 EPS. The business’s revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts anticipate that Medtronic PLC will post 5.57 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were issued a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.5%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: EU market access expands for Medtronic’s integrated robotics/navigation platform — Stealth AXiS received a CE mark, enabling rollout for spine and cranial procedures across Europe and accelerating the company’s robotics/navigation strategy after recent U.S. clearances. This supports longer-term revenue upside for Medtronic’s surgical robotics and navigation franchise. Medtronic announces CE Mark for Stealth AXiS™ surgical system Medtronic wins CE mark for Stealth AXiS surgical robot platform
• Positive Sentiment: Regulatory and clinical wins in cardiac care — Medtronic secured FDA Breakthrough Device designation for its Sphere‑9 VT catheter and reported clinical milestones (Affera), which could speed commercialization in a high‑value electrophysiology market and improve growth prospects for the cardiac franchise. Medtronic wins FDA breakthrough nod for Sphere-9 catheter, reports new clinical milestones for Affera
• Positive Sentiment: Geographic expansion: launch of Adaptive Deep Brain Stimulation (aDBS) in India broadens addressable market for neuromodulation and supports incremental revenue and adoption in emerging markets. Medtronic Launches Adaptive Deep Brain Stimulation System for Parkinson’s Patients in India
• Neutral Sentiment: Analyst views are mixed — recent coverage highlights divergent opinions on valuation and near‑term growth, which can sustain volatility but also create opportunities if execution improves. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Neogen (NEOG) and Community Health (CYH)
• Neutral Sentiment: Industry context: peer data and J&J’s medtech momentum show improving end‑market dynamics but also highlight lingering China headwinds and product competition — relevant for Medtronic’s medtech peers. J&J Sees Continued MedTech Improvement in Q1, Eyes Better 2026
• Negative Sentiment: Cybersecurity disclosure is a near‑term overhang — Medtronic reported unauthorized access to portions of its IT systems, saying operations, manufacturing and patient safety were not affected and no material financial impact is expected. Investors typically penalize such disclosures due to data‑risk and remediation costs uncertainty. Medtronic says cyberattack on IT network has not disrupted operations Medtronic says cyberattack on IT network has not disrupted operations (Yahoo)
• Negative Sentiment: Competitive pressure in electrophysiology — new pulsed‑field ablation (PFA) data and market share moves highlighted at HRS create execution risk for Medtronic’s EP business; market share erosion or slower adoption could weigh on near‑term growth. 4 studies to know from HRS 2026 HRS 2026: Medtronic, Boston Scientific and Abbott debut key PFA data
• Negative Sentiment: Near‑term share reaction and trading activity — coverage noting that MDT has fallen more than the broader market and the stock is trading lower today reflects investor caution as the above negatives and mixed analyst views are digested; expect continued volatility until clarity on cyber remediation and execution on new products. Medtronic (MDT) Falls More Steeply Than Broader Market: What Investors Need to Know Medtronic (MDT) Falls More Steeply Than Broader Market (Zacks)

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on MDT shares. Needham & Company LLC restated a “buy” rating and set a $120.00 target price on shares of Medtronic in a report on Thursday, March 26th. Wall Street Zen cut Medtronic from a “buy” rating to a “hold” rating in a report on Saturday, April 11th. Argus dropped their target price on Medtronic from $125.00 to $115.00 and set a “buy” rating for the company in a report on Monday, April 6th. Evercore set a $106.00 target price on Medtronic and gave the company an “outperform” rating in a report on Thursday, April 9th. Finally, Truist Financial dropped their target price on Medtronic from $103.00 to $95.00 and set a “hold” rating for the company in a report on Wednesday, April 15th. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.80.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).